Financing to biotech companies in North American and Europe declined in 2012 as debt funding decreased and the IPO market remained weak.
May 3, 2013
By:
Patricia Van Arnum
Financing to biotech companies in North American and Europe declined in 2012 as debt funding decreased and the IPO market remained weak.
|
Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Sanofi, and Roche are among the companies expanding biologic-based manufacturing capacity.
May 3, 2013
By:
Patricia Van Arnum
Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Sanofi, and Roche are among the companies expanding biologic-based manufacturing capacity.
|
The Global Vaccine Action plan maps out a strategy to increase access and R&D for vaccines.
May 3, 2013
By:
Patricia Van Arnum
The Global Vaccine Action plan maps out a strategy to increase access and R&D for vaccines.
|
Solid-state chemistry is an important part of drug development, and public research is advancing the field.
May 2, 2013
By:
Patricia Van Arnum
Solid-state chemistry is an important part of drug development, and public research is advancing the field.
|
Cocrystals are used to improve the performance of APIs that have non-ideal physiochemical properties.
May 2, 2013
By:
Patricia Van Arnum
Cocrystals are used to improve the performance of APIs that have non-ideal physiochemical properties by cocrystallizing the API with a second compound that modulates the API to provide a way to improve a drug's bioavailability, stability, and processability.
|
|
The rejection by India's Supreme Court on Novartis' Glivec/Gleevec (imatinib mesylate) and other recent case law raise important issues on patent strategies for solid forms.
May 2, 2013
By:
Patricia Van Arnum
The rejection by India's Supreme Court on Novartis' Glivec/Gleevec (imatinib mesylate) and other recent case law raise important issues on patent strategies for solid forms.
|
|
Despite overall manufacturing rationalization in the pharmaceutical/biopharmaceutical industry, the large pharmaceutical companies continue to invest in biologic-based manufacturing.
May 1, 2013
By:
Patricia Van Arnum
Despite overall manufacturing rationalization in the pharmaceutical/biopharmaceutical industry, the large pharmaceutical companies continue to invest in biologic-based manufacturing. The author provides an update in recent investment activity among the pharmaceutical majors in biologic-drug substance, vaccine, and parenteral drug manufacturing.
|
|
Parenteral drug delivery offers a variety of challenges but also opportunities.
May 1, 2013
By:
Patricia Van Arnum
Parenteral drug delivery offers a variety of challenges but also opportunities. The author examines recent developments in nanotechnology-based drug delivery and other advances in injection-based drug delivery.
|
The company expands to add process-development and clinical-manufacturing capabilities at its large-scale bulk biologics facility.
Apr 12, 2013
By:
Patricia Van Arnum
The company expands to add process-development and clinical-manufacturing capabilities at its large-scale bulk biologics facility.
|
|
